TY - JOUR AU - Smolen, J. S. AU - Landewe, R. AU - Breedveld, F. C. AU - Buch, M. AU - Burmester, G. AU - Dougados, M. PY - 2014 DA - 2014// TI - EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-204573 DO - 10.1136/annrheumdis-2013-204573 ID - Smolen2014 ER - TY - JOUR AU - Espinoza, F. AU - Fabre, S. AU - Pers, Y. -. M. PY - 2016 DA - 2016// TI - Remission-induction therapies for early rheumatoid arthritis: evidence to date and clinical implications JO - Ther Adv Musculoskelet Dis VL - 8 UR - https://doi.org/10.1177/1759720X16654476 DO - 10.1177/1759720X16654476 ID - Espinoza2016 ER - TY - JOUR AU - Prevoo, M. L. AU - van’t Hof, M. A. AU - Kuper, H. H. AU - Leeuwen, M. A. AU - Putte, L. B. AU - Riel, P. L. PY - 1995 DA - 1995// TI - Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis JO - Arthritis Rheum VL - 38 UR - https://doi.org/10.1002/art.1780380107 DO - 10.1002/art.1780380107 ID - Prevoo1995 ER - TY - JOUR AU - Aletaha, D. AU - Smolen, J. PY - 2005 DA - 2005// TI - The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis JO - Clin Exp Rheumatol VL - 23 ID - Aletaha2005 ER - TY - JOUR AU - Smolen, J. S. AU - Landewe, R. AU - Bijlsma, J. AU - Burmester, G. AU - Chatzidionysiou, K. AU - Dougados, M. PY - 2017 DA - 2017// TI - EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update JO - Ann Rheum Dis VL - 76 UR - https://doi.org/10.1136/annrheumdis-2016-210715 DO - 10.1136/annrheumdis-2016-210715 ID - Smolen2017 ER - TY - JOUR AU - Fautrel, B. AU - Verstappen, S. M. M. AU - Boonen, A. PY - 2011 DA - 2011// TI - Economic consequences and potential benefits JO - Best Pract Res Clin Rheumatol VL - 25 UR - https://doi.org/10.1016/j.berh.2011.10.001 DO - 10.1016/j.berh.2011.10.001 ID - Fautrel2011 ER - TY - JOUR AU - Maas, A. AU - Kievit, W. AU - Bemt, B. J. F. AU - Hoogen, F. H. J. AU - Riel, P. L. AU - Broeder, A. A. PY - 2012 DA - 2012// TI - Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study JO - Ann Rheum Dis VL - 71 UR - https://doi.org/10.1136/annrheumdis-2011-200945 DO - 10.1136/annrheumdis-2011-200945 ID - Maas2012 ER - TY - JOUR AU - Tanaka, Y. AU - Takeuchi, T. AU - Mimori, T. AU - Saito, K. AU - Nawata, M. AU - Kameda, H. PY - 2010 DA - 2010// TI - Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study JO - Ann Rheum Dis VL - 69 UR - https://doi.org/10.1136/ard.2009.121491 DO - 10.1136/ard.2009.121491 ID - Tanaka2010 ER - TY - JOUR AU - Kooij, S. M. AU - Goekoop-Ruiterman, Y. P. M. AU - Vries-Bouwstra, J. K. AU - Guler-Yuksel, M. AU - Zwinderman, A. H. AU - Kerstens, P. J. S. M. PY - 2009 DA - 2009// TI - Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis JO - Ann Rheum Dis VL - 68 UR - https://doi.org/10.1136/ard.2008.092254 DO - 10.1136/ard.2008.092254 ID - Kooij2009 ER - TY - JOUR AU - Kuijper, T. M. AU - Lamers-Karnebeek, F. B. G. AU - Jacobs, J. W. G. AU - Hazes, J. M. W. AU - Luime, J. J. PY - 2015 DA - 2015// TI - Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review JO - J Rheumatol VL - 42 UR - https://doi.org/10.3899/jrheum.141520 DO - 10.3899/jrheum.141520 ID - Kuijper2015 ER - TY - STD TI - EMA. RoActemra (tocilizumab). Summary of Product Characteristics. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf. Accessed 18 Nov 2019. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf ID - ref11 ER - TY - JOUR AU - Aguilar-Lozano, L. AU - Castillo-Ortiz, J. D. AU - Vargas-Serafin, C. AU - Morales-Torres, J. AU - Sanchez-Ortiz, A. AU - Sandoval-Castro, C. PY - 2013 DA - 2013// TI - Sustained clinical remission and rate of relapse after tocilizumab withdrawal in patients with rheumatoid arthritis JO - J Rheumatol VL - 40 UR - https://doi.org/10.3899/jrheum.121427 DO - 10.3899/jrheum.121427 ID - Aguilar-Lozano2013 ER - TY - JOUR AU - Nishimoto, N. AU - Amano, K. AU - Hirabayashi, Y. AU - Horiuchi, T. AU - Ishii, T. AU - Iwahashi, M. PY - 2014 DA - 2014// TI - Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study JO - Mod Rheumatol VL - 24 UR - https://doi.org/10.3109/14397595.2013.854079 DO - 10.3109/14397595.2013.854079 ID - Nishimoto2014 ER - TY - JOUR AU - Kikuchi, J. u. n. AU - Kondo, T. s. u. n. e. o. AU - Shibata, A. k. i. k. o. AU - Sakai, R. y. o. t. a. AU - Okada, Y. u. s. u. k. e. AU - Chino, K. e. n. t. a. r. o. AU - Okuyama, A. y. u. m. i. AU - Kurasawa, T. a. k. a. h. i. k. o. AU - Takei, H. i. r. o. f. u. m. i. AU - Amano, K. o. i. c. h. i. PY - 2017 DA - 2017// TI - Efficacy and tolerability of six-week extended dosing interval with tocilizumab therapy in a prospective cohort as remission maintenance in patients with rheumatoid arthritis JO - Modern Rheumatology VL - 28 UR - https://doi.org/10.1080/14397595.2017.1366092 DO - 10.1080/14397595.2017.1366092 ID - Kikuchi2017 ER - TY - JOUR AU - Nestorov, I. PY - 2005 DA - 2005// TI - Clinical pharmacokinetics of TNF antagonists: how do they differ? JO - Semin Arthritis Rheum VL - 34 UR - https://doi.org/10.1016/j.semarthrit.2005.01.004 DO - 10.1016/j.semarthrit.2005.01.004 ID - Nestorov2005 ER - TY - JOUR AU - Combe, B. AU - Landewe, R. AU - Lukas, C. AU - Bolosiu, H. D. AU - Breedveld, F. AU - Dougados, M. PY - 2007 DA - 2007// TI - EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) JO - Ann Rheum Dis VL - 66 UR - https://doi.org/10.1136/ard.2005.044354 DO - 10.1136/ard.2005.044354 ID - Combe2007 ER - TY - JOUR AU - Saleem, B. AU - Keen, H. AU - Goeb, V. AU - Parmar, R. AU - Nizam, S. AU - Hensor, E. M. A. PY - 2010 DA - 2010// TI - Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? JO - Ann Rheum Dis VL - 69 UR - https://doi.org/10.1136/ard.2009.117341 DO - 10.1136/ard.2009.117341 ID - Saleem2010 ER - TY - JOUR AU - Lau, C. S. AU - Gibofsky, A. AU - Damjanov, N. AU - Lula, S. AU - Marshall, L. AU - Jones, H. PY - 2017 DA - 2017// TI - Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review JO - Rheumatol Int VL - 37 UR - https://doi.org/10.1007/s00296-017-3780-8 DO - 10.1007/s00296-017-3780-8 ID - Lau2017 ER - TY - JOUR AU - Smolen, J. S. AU - Nash, P. AU - Durez, P. AU - Hall, S. AU - Ilivanova, E. AU - Irazoque-Palazuelos, F. PY - 2013 DA - 2013// TI - Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial JO - Lancet VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61811-X DO - 10.1016/S0140-6736(12)61811-X ID - Smolen2013 ER - TY - JOUR AU - Chatzidionysiou, K. AU - Turesson, C. AU - Teleman, A. AU - Knight, A. AU - Lindqvist, E. AU - Larsson, P. PY - 2016 DA - 2016// TI - A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission JO - RMD open VL - 2 UR - https://doi.org/10.1136/rmdopen-2015-000133 DO - 10.1136/rmdopen-2015-000133 ID - Chatzidionysiou2016 ER - TY - JOUR AU - Smolen, J. S. AU - Emery, P. AU - Ferraccioli, G. F. AU - Samborski, W. AU - Berenbaum, F. AU - Davies, O. R. PY - 2015 DA - 2015// TI - Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial JO - Ann Rheum Dis VL - 74 UR - https://doi.org/10.1136/annrheumdis-2013-204632 DO - 10.1136/annrheumdis-2013-204632 ID - Smolen2015 ER - TY - JOUR AU - Vollenhoven, R. F. AU - Ostergaard, M. AU - Leirisalo-Repo, M. AU - Uhlig, T. AU - Jansson, M. AU - Larsson, E. PY - 2016 DA - 2016// TI - Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2014-205726 DO - 10.1136/annrheumdis-2014-205726 ID - Vollenhoven2016 ER - TY - JOUR AU - Fautrel, B. AU - Pham, T. AU - Alfaiate, T. AU - Gandjbakhch, F. AU - Foltz, V. AU - Morel, J. PY - 2016 DA - 2016// TI - Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2014-206696 DO - 10.1136/annrheumdis-2014-206696 ID - Fautrel2016 ER - TY - JOUR AU - Mulligen, E. AU - Jong, P. H. P. AU - Kuijper, T. M. AU - Ven, M. AU - Appels, C. AU - Bijkerk, C. PY - 2019 DA - 2019// TI - Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study JO - Ann Rheum Dis VL - 78 UR - https://doi.org/10.1136/annrheumdis-2018-214970 DO - 10.1136/annrheumdis-2018-214970 ID - Mulligen2019 ER - TY - JOUR AU - Saiki, O. AU - Uda, H. PY - 2017 DA - 2017// TI - Successful extension of tocilizumab infusion intervals from 4 weeks to 6 or 5 weeks in 90% of RA patients with good response to 4-week intervals JO - Clin Exp Rheumatol VL - 35 ID - Saiki2017 ER - TY - JOUR AU - Saiki, O. AU - Uda, H. PY - 2018 DA - 2018// TI - Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals JO - Rheumatol Int VL - 38 UR - https://doi.org/10.1007/s00296-018-4149-3 DO - 10.1007/s00296-018-4149-3 ID - Saiki2018 ER - TY - JOUR AU - Bouman, C. A. M. AU - Tweehuysen, L. AU - Haverkort, D. AU - Ende, C. H. AU - Maas, A. AU - Broeder, A. A. PY - 2018 DA - 2018// TI - Abatacept and tocilizumab tapering in rheumatoid arthritis patients: results of SONATA-a retrospective, exploratory cohort study JO - Rheumatol Adv Pract VL - 2 UR - https://doi.org/10.1093/rap/rky008 DO - 10.1093/rap/rky008 ID - Bouman2018 ER - TY - JOUR AU - Huizinga, T. W. J. AU - Conaghan, P. G. AU - Martin-Mola, E. AU - Schett, G. AU - Amital, H. AU - Xavier, R. M. PY - 2015 DA - 2015// TI - Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study JO - Ann Rheum Dis VL - 74 UR - https://doi.org/10.1136/annrheumdis-2014-205752 DO - 10.1136/annrheumdis-2014-205752 ID - Huizinga2015 ER - TY - JOUR AU - Woude, D. AU - Young, A. AU - Jayakumar, K. AU - Mertens, B. J. AU - Toes, R. E. M. AU - Heijde, D. PY - 2009 DA - 2009// TI - Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts JO - Arthritis Rheum VL - 60 UR - https://doi.org/10.1002/art.24661 DO - 10.1002/art.24661 ID - Woude2009 ER -